Limoges University Hospital Dupuytren 1 — Clinical Trial Site

11 Registered trials

6 Currently recruiting

Organisation

Limoges University Hospital Dupuytren 1

Location

Limoges Cedex 1, France

Identifier

ORG-100032548

Address

2 Avenue Martin Luther King, 87042, France

Departments

Hématologie Clinique et Thérapie Cellulaire
hepatogastroenterologie
Intensive Care Medicine
N/A
Nephrology
oncology
Pneumology
Service d'Hépato-gastro-entérologie
Service d'Oncologie Médicale
Unité de recherche clinique en oncologie

Clinical trials at this site (11)

Search interface

PRODIGE 88-CIRCULATE PAC: Phase III multicentric, open-label, randomized study to investigate the efficacy of chemotherapy in patients with … Recruiting

2023-505046-26-00 Colon carcinoma 5 2026-05-07
ERASE PH-COPD Recruiting

2022-500862-93-00 Pulmonary Hypertension 5 2024-02-01
INduction in Sensitized kidney Transplant recipients without pre-Existing donor-specific AntiboDies: a randomized multicentre trial between … Recruiting

2022-502007-30-00 Kidney transplant 5 2023-11-07
Study evaluating thromboprophylaxis in patients with advanced germ cell tumours of good or intermediate prognosis Recruiting

2022-502426-41-00 Thromboprophylaxis in good and intermediate prognosis a 5 2023-10-17
FLUCLORIC - Randomized multicentric Phase III study comparing the efficacy of two reduced intensity conditioning regimens (clofarabine/busul… Recruiting

2022-502019-12-00 acute myeloid leukemia 5 2023-09-14
Evaluation of an initial treatment with bevacizumab in combination with chemotherapy and then in combination with niraparib in maintenance i… Recruiting

2023-504166-37-00 Advanced ovarian, tubal or peritoneal cancer. 4 2022-02-01
Clinical trial for the treatment of COVID-19 and COVID-like illness in primary care Ended

2022-501707-27-01 COVID-like-illness 10 2024-10-03
PhII Trial of Pembrolizumab in Advanced Solid Tumors Ended

2022-501253-37-00 (A) Anal Squamous Cell Carcinoma, (B) Biliary Adenocarc 4 2016-02-02
Phase 2 Study of CAL02 plus Standard of Care in Severe Community-Acquired Bacterial Pneumonia (SCABP) Halted

2022-502049-91-00 SEVERE COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (SCABP) 4 2023-09-26
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) Ended

2022-502899-23-00 Hepatic Encephalopathy (OHE) 5 2024-04-23
Ezurpimtrostat autophagy inhibitor in association with Atezolizumab-Bevacizumab in first line treatment of unresectable hepatocellular carci… Ended

2022-502078-17-00 unresectable hepatocellular carcinoma 4 2022-12-15